• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在癌症门诊患者中使用通用不良事件术语标准和其他患者报告症状结局工具进行常规评估的可接受性:玛格丽特公主癌症中心的经验。

Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.

机构信息

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Northern Beaches Cancer Service, Sydney, New South Wales, Australia.

出版信息

Oncologist. 2019 Nov;24(11):e1219-e1227. doi: 10.1634/theoncologist.2018-0830. Epub 2019 Aug 13.

DOI:10.1634/theoncologist.2018-0830
PMID:31409744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6853088/
Abstract

BACKGROUND

Recent studies have demonstrated improved outcomes with real-time patient-reported outcome questionnaires (PRO questionnaires) using questions adapted for patient use from the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). Outside of the clinical trial setting, limited information exists on factors affecting the completion of PRO questionnaires in routine practice. The primary aim of this prospective cross-sectional study was to evaluate patient willingness to complete PRO questionnaires on a regular basis and to better understand responder biases to improve patient feedback.

MATERIALS AND METHODS

Patients performing PRO-CTCAE toxicity and symptom PRO questionnaires in oncology clinics at Princess Margaret Cancer Centre from 2013 to 2016 were assessed for their willingness to complete PRO questionnaires using a nine-item, tablet-based acceptability survey. Patient-reported characteristics (i.e., age, sex, language, marital status, education, occupation, etc.), cancer type, treatment modalities, and health metrics (i.e., Eastern Cooperative Oncology Group) were also collected. Characteristics were evaluated by logistic regression (odds ratios [OR]) using the primary outcome with prespecified levels of significance for univariate ( ≤ .10), and additional multivariate ( ≤ .05) testing.

RESULTS

A total of 1,792 patients (median age 60 years; range 18-97) with various cancer diagnoses were assessed. A greater proportion of female (56%) and white (74%) respondents with an annual household income of <$100,000 (69%) participated. More than half (58%) of respondents were willing to complete PRO questionnaires at every clinic visit, and a high proportion (77%) found utility in reporting physical and emotional feelings to clinicians using PRO questionnaires. In general, patients did not find that PRO questionnaires made clinic visits more difficult (93%). In uni- and multivariable testing, patients were more willing to complete sleep- and fatigue-related PRO questionnaires relative to chemotoxicity-based PRO questionnaires (OR 1.52; = .012). Patients aged 40-65 versus 18-40 years were also more likely to report high PRO questionnaire acceptability (OR 1.49; = .025). Additional patient characteristics such as white ethnicity (OR 1.76), Canada as country of birth (OR 1.66), and English language (OR 2.15) relative to other had higher acceptability on uni- ( < .001) and multivariable ( < .001) analyses. Patients reporting treatment intent as palliative (OR 0.69; = .0013) or hematological (OR 0.73; = .027) were less likely to report high PRO questionnaire acceptability on univariable analysis; however, only palliative patients (OR 0.72) maintained this effect on multivariable testing ( = .012). Patients reporting higher health utility scores (per change in .05) also had significantly increased PRO questionnaire acceptability in uni- (OR 1.06; < .001) and multivariable (OR 1.05; = .008) analyses. No significant differences in PRO questionnaire acceptability were seen between cancer types, education level, household income, employment status, or treatment modality.

CONCLUSION

Routine assessment using PRO questionnaires is associated with moderate acceptability by patients with cancer. Specific patient characteristics are associated with higher completion willingness. Additional research is necessary to identify factors associated with low acceptability of PRO questionnaires and to develop site-, ethnicity-, and treatment-specific instruments to assess the value of PRO questionnaires for symptom monitoring in clinical practice.

IMPLICATIONS FOR PRACTICE

This study will help to identify the clinical, demographic, and survey characteristics associated with willingness to complete patient-reported outcome questionnaires regularly in the cancer outpatient setting.

摘要

背景

最近的研究表明,使用从国立癌症研究所的常见不良事件术语标准(CTCAE)改编为患者使用的问题的实时患者报告结局问卷(PRO 问卷)可以改善结局。在临床试验环境之外,关于影响常规实践中 PRO 问卷完成的因素的信息有限。本前瞻性横断面研究的主要目的是评估患者定期完成 PRO 问卷的意愿,并更好地了解应答者偏差以改善患者反馈。

材料和方法

从 2013 年至 2016 年,在玛格丽特公主癌症中心的肿瘤诊所进行 PRO-CTCAE 毒性和症状 PRO 问卷的患者使用基于平板电脑的九项可接受性调查评估其完成 PRO 问卷的意愿。患者报告的特征(即年龄、性别、语言、婚姻状况、教育、职业等)、癌症类型、治疗方式和健康指标(即东部肿瘤协作组)也被收集。使用逻辑回归(优势比[OR])评估特征,使用单变量(≤.10)和额外多变量(≤.05)测试的预设显着性水平。

结果

共有 1792 名(中位数年龄 60 岁;范围 18-97)患有各种癌症诊断的患者接受了评估。更多的女性(56%)和白人(74%)受访者参加了年收入<$100,000(69%)的调查。超过一半(58%)的受访者愿意在每次就诊时完成 PRO 问卷,并且很大一部分(77%)发现使用 PRO 问卷向临床医生报告身体和情绪感受很有用。一般来说,患者认为 PRO 问卷不会使就诊更加困难(93%)。在单变量和多变量测试中,与基于化疗毒性的 PRO 问卷相比,患者更愿意完成与睡眠和疲劳相关的 PRO 问卷(OR 1.52;=.012)。与 18-40 岁的患者相比,年龄在 40-65 岁的患者也更有可能报告高 PRO 问卷可接受性(OR 1.49;=.025)。其他患者特征,如白种人(OR 1.76)、加拿大出生(OR 1.66)和英语(OR 2.15)相对于其他语言,在单变量(<.001)和多变量(<.001)分析中具有更高的可接受性。报告治疗意图为姑息治疗(OR 0.69;=.0013)或血液学(OR 0.73;=.027)的患者不太可能在单变量分析中报告高 PRO 问卷可接受性;然而,只有姑息治疗患者(OR 0.72)在多变量测试中保持了这种效果(=.012)。报告更高健康效用评分(每变化.05)的患者在单变量(OR 1.06;<.001)和多变量(OR 1.05;=.008)分析中也具有显着增加的 PRO 问卷可接受性。不同癌症类型、教育水平、家庭收入、就业状况或治疗方式之间的 PRO 问卷可接受性没有显着差异。

结论

使用 PRO 问卷进行常规评估与癌症患者的中等可接受性相关。特定的患者特征与更高的完成意愿相关。需要进一步研究以确定与 PRO 问卷低可接受性相关的因素,并开发针对特定地点、种族和治疗的工具,以评估 PRO 问卷在临床实践中用于症状监测的价值。

实践意义

本研究将有助于确定与癌症门诊环境中定期完成患者报告结局问卷相关的临床、人口统计学和调查特征。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/6853088/5966ee58027c/onco13052-fig-0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/6853088/93404e232326/onco13052-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/6853088/5966ee58027c/onco13052-fig-0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/6853088/93404e232326/onco13052-fig-0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/654c/6853088/5966ee58027c/onco13052-fig-0002.jpg

相似文献

1
Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.在癌症门诊患者中使用通用不良事件术语标准和其他患者报告症状结局工具进行常规评估的可接受性:玛格丽特公主癌症中心的经验。
Oncologist. 2019 Nov;24(11):e1219-e1227. doi: 10.1634/theoncologist.2018-0830. Epub 2019 Aug 13.
2
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国家癌症研究所患者报告结局版通用不良事件术语标准(PRO-CTCAE)的有效性和可靠性。
JAMA Oncol. 2015 Nov;1(8):1051-9. doi: 10.1001/jamaoncol.2015.2639.
3
Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).美国国立癌症研究所不良事件通用术语标准患者报告结局(PRO-CTCAE)的平板电脑、交互式语音应答系统和纸质管理方式的模式等效性与可接受性
Health Qual Life Outcomes. 2016 Feb 19;14:24. doi: 10.1186/s12955-016-0426-6.
4
Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.对美国国立癌症研究所的PRO-CTCAE不同召回期的评估。
Clin Trials. 2017 Jun;14(3):255-263. doi: 10.1177/1740774517698645. Epub 2017 Mar 20.
5
Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).使用美国国家癌症研究所的患者报告结局版常见不良事件术语标准(PRO-CTCAE),对癌症临床研究中的症状性不良事件进行患者自由文本报告。
J Am Med Inform Assoc. 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.
6
Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.美国国家癌症研究所患者报告结局通用术语标准不良事件的韩语版的可靠性和有效性。
J Pain Symptom Manage. 2020 May;59(5):1082-1088.e6. doi: 10.1016/j.jpainsymman.2020.01.015. Epub 2020 Feb 8.
7
Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.将儿童和青少年自我报告的症状数据与临床医生报告的不良事件分级进行映射,以改善儿科肿瘤学的护理和研究。
Cancer. 2020 Jan 1;126(1):140-147. doi: 10.1002/cncr.32525. Epub 2019 Sep 25.
8
Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.患者与临床医生报告的不良症状事件:与临床结局的关系
J Natl Cancer Inst. 2009 Dec 2;101(23):1624-32. doi: 10.1093/jnci/djp386. Epub 2009 Nov 17.
9
Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care.患者报告结局测量信息系统(PROMIS)项目库用于常规监测门诊癌症护理中的睡眠和疲劳问题的可行性和诊断准确性。
Cancer. 2016 Sep 15;122(18):2906-17. doi: 10.1002/cncr.30134. Epub 2016 Jun 28.
10
Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study.在放化疗期间,使用患者报告的不良事件通用术语标准的患者报告结局版本对各种癌症患者的症状负担进行监测:真实世界研究。
JMIR Public Health Surveill. 2023 Mar 8;9:e44105. doi: 10.2196/44105.

引用本文的文献

1
Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients.移民背景对晚期尿路上皮癌患者电子患者报告结局可行性的影响。
Health Qual Life Outcomes. 2024 Dec 18;22(1):107. doi: 10.1186/s12955-024-02325-z.
2
Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.患者对酪氨酸激酶抑制剂治疗非小细胞肺癌相关治疗毒性及治疗药物监测的观点。
Ther Adv Med Oncol. 2024 Dec 7;16:17588359241303403. doi: 10.1177/17588359241303403. eCollection 2024.
3

本文引用的文献

1
Patient-reported outcomes in cancer care - hearing the patient voice at greater volume.癌症护理中的患者报告结局 - 更大程度地倾听患者的声音。
Nat Rev Clin Oncol. 2017 Dec;14(12):763-772. doi: 10.1038/nrclinonc.2017.153. Epub 2017 Oct 4.
2
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment.一项评估常规癌症治疗期间症状监测的患者报告结局的试验的总生存结果。
JAMA. 2017 Jul 11;318(2):197-198. doi: 10.1001/jama.2017.7156.
3
Automated home monitoring and management of patient-reported symptoms during chemotherapy: results of the symptom care at home RCT.
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.
弥合差距:个性化癌症医学实施综述
J Pers Med. 2024 May 24;14(6):561. doi: 10.3390/jpm14060561.
4
Nonresponse data in sexual well-being among breast reconstruction patients-who are we overlooking?乳房再造患者性健康中的无应答数据——我们忽略了谁?
J Surg Oncol. 2024 Jun;129(7):1192-1201. doi: 10.1002/jso.27639. Epub 2024 Apr 7.
5
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E-RADIatE OligoCare cohort.寡转移前列腺癌患者在转移灶定向立体定向体部放疗后的健康相关生活质量:来自E-RADIatE OligoCare队列的真实世界数据。
Clin Transl Radiat Oncol. 2023 Dec 29;45:100715. doi: 10.1016/j.ctro.2023.100715. eCollection 2024 Mar.
6
Assessing Patient Readiness for an Electronic Patient-Reported Outcome-Based Symptom Management Intervention in a Multisite Study.评估患者对基于电子患者报告结局的症状管理干预措施的准备情况,该措施是在一项多中心研究中进行的。
JCO Oncol Pract. 2024 Jan;20(1):77-84. doi: 10.1200/OP.23.00339. Epub 2023 Nov 27.
7
Symptoms and Needs Monitoring in Diverse Ambulatory Oncology Patients: Usage Characteristics and Impact on Emergency Room Visits and Hospitalization.不同门诊肿瘤患者的症状与需求监测:使用特征及其对急诊就诊和住院的影响
J Clin Oncol. 2023 Jan 10;41(2):285-294. doi: 10.1200/JCO.22.01038. Epub 2022 Oct 11.
8
Who Are We Missing: Does Engagement in Patient-Reported Outcome Measures for Breast Cancer Vary by Age, Race, or Disease Stage?我们遗漏了谁:参与乳腺癌患者报告结局测量是否因年龄、种族或疾病阶段而异?
Ann Surg Oncol. 2022 Dec;29(13):7964-7973. doi: 10.1245/s10434-022-12477-1. Epub 2022 Sep 23.
9
Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: A single-center registry experience.接受放疗的乳腺癌患者的患者报告结局:一项单中心注册研究经验。
Front Oncol. 2022 Aug 26;12:920739. doi: 10.3389/fonc.2022.920739. eCollection 2022.
10
A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring.电子患者报告结局在癌症生存者照护中的采集和应用述评,重点关注症状监测。
Curr Oncol. 2022 Jun 17;29(6):4370-4385. doi: 10.3390/curroncol29060349.
化疗期间患者自我报告症状的自动化家庭监测与管理:居家症状护理随机对照试验的结果
Cancer Med. 2017 Mar;6(3):537-546. doi: 10.1002/cam4.1002. Epub 2017 Jan 30.
4
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.常规癌症治疗期间通过患者报告结局进行症状监测:一项随机对照试验。
J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7.
5
Alpha emitter radium-223 and survival in metastatic prostate cancer.α 粒子发射体镭-223 与转移性前列腺癌的生存。
N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.
6
Late response to patient-reported outcome questionnaires after surgery was associated with worse outcome.术后对患者报告的结局调查问卷的迟回复与较差的结局相关。
J Clin Epidemiol. 2013 Feb;66(2):218-25. doi: 10.1016/j.jclinepi.2012.09.001. Epub 2012 Nov 28.
7
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology.将患者报告结局纳入成人肿瘤临床对照有效性研究的建议。
J Clin Oncol. 2012 Dec 1;30(34):4249-55. doi: 10.1200/JCO.2012.42.5967. Epub 2012 Oct 15.
8
Factors associated with non-response in routine use of patient reported outcome measures after elective surgery in England.与英国择期手术后常规使用患者报告结局测量时无应答相关的因素。
Health Qual Life Outcomes. 2012 Mar 30;10:34. doi: 10.1186/1477-7525-10-34.
9
Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.加拿大对 EQ-5D 健康状态的评估:初步价值集及对未来评估研究的考虑。
PLoS One. 2012;7(2):e31115. doi: 10.1371/journal.pone.0031115. Epub 2012 Feb 6.
10
Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival.患者自我报告的症状和临床医生的评分作为总体癌症生存的预测因素。
J Natl Cancer Inst. 2011 Dec 21;103(24):1851-8. doi: 10.1093/jnci/djr485. Epub 2011 Dec 7.